ESH CLL 2022 – Federico Pea
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationFederico Pea draws attention to the most relevant differences between first-generation and next-generation BTK inhibitors observed at the pharmacokinetic level in terms of antitumor activity, how differences in kinase selectivity affect the tolerability of these drugs, which patient groups appear suitable for first-generation or next-generation BTK inhibitor therapy and outlines, from a pharmacologists point of view, what clinicians should keep in mind when treating CLL patients with BTK inhibitors.